Table 3.
Summary of adverse events (AEs) reported during part I by frequency
| Treatment A (n = 20) | Treatment B1 (n = 20) | Treatment B2 (n = 20) | Overall (n = 20) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred term | AEs | n | % | AEs | n | % | AEs | n | % | AEs | n | % |
| Number of subjects with at least one AE | 15 | 75 | 3 | 15 | 20 | 100 | 20 | 100 | ||||
| Number of different AEs | 3 | 2 | 11 | 12 | ||||||||
| Total number of AEs | 17 | 3 | 74 | 94 | ||||||||
| Headache | 15 | 14 | 70 | 1 | 1 | 5 | 20 | 18 | 90 | 36 | 18 | 90 |
| Nausea | 18 | 15 | 75 | 18 | 15 | 75 | ||||||
| Vomiting | 23 | 12 | 60 | 23 | 12 | 60 | ||||||
| Pain in extremity | 1 | 1 | 5 | 4 | 3 | 15 | 5 | 3 | 15 | |||
| Diarrhoea | 2 | 2 | 10 | 1 | 1 | 5 | 3 | 3 | 15 | |||
| Myalgia | 2 | 2 | 10 | 2 | 2 | 10 | ||||||
| Pain in jaw | 2 | 2 | 10 | 2 | 2 | 10 | ||||||
| Presyncope | 1 | 1 | 5 | 1 | 1 | 5 | ||||||
| Dyspepsia | 1 | 1 | 5 | 1 | 1 | 5 | ||||||
| Arthralgia | 1 | 1 | 5 | 1 | 1 | 5 | ||||||
| Neck pain | 1 | 1 | 5 | 1 | 1 | 5 | ||||||
| Nasopharyngitis | 1 | 1 | 5 | 1 | 1 | 5 | ||||||
Treatments: A = selexipag; B1 = gemfibrozil; B2 = gemfibrozil + selexipag. Data are expressed as AE (number of adverse events), n (number of subjects experiencing at least one AE) and % (percentage of subjects with at least one AE)